Cold . . . is not so cold: CD4+ T cells are active but suppressed in colorectal cancer

J. Milburn Jessup

DOI: https://doi.org/10.4049/jimmunol.202.supp.136.8

2019-05-01

The Journal of Immunology

Abstract:Abstract Introduction Checkpoint inhibitors blocking the PD-1/PD-L1 axis or CTLA4 are standard of care for lung and kidney cancer and melanoma. However, colorectal carcinoma (CRC), the second most lethal cancer in the US, has only a 7% response rate to checkpoint inhibitors because more than 60% of CRC lack tumor infiltrating lymphocytes, PD-L1 expression, or have low mutational burden. We postulated that cellular immune responses to autologous tumor antigens in patients with CRC are present but suppressed. Methods Patients with stage I – III CRC were studied as part of a vaccine program to determine cellular immunity to their autologous tumor. Single cell suspensions of tumor and normal mucosa were made and cryopreserved from each patient. All patients had IgG or IgA antibodies that reacted with autologous tumor by indirect immunofluorescence. Peripheral blood mononuclear cells (PBMC) were isolated and CD4+ and CD8+ T cell subsets were cultured with Mitomycin C-treated autologous Tumor or mucosal cells. Proliferation was measured after 3 days by 3H-thymidine post-labeling. Results 4 of 5 unvaccinated patients had CD4+ T cell subset proliferation whereas PBMC or CD8+ T cell subsets did not. When CD8+ T cells were added back to CD4+ T cells, proliferation was inhibited. Patients vaccinated with BCG and autologous tumor cells displayed specific cellular-immune responses for up to 9 months. Conclusion CRC patients with T-dependent IgG or IgA autoantibodies frequently contain a CD4+ T cell subset that may be boosted to support systemic immunity or, possibly, checkpoint inhibitor therapy.

immunology